1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades Infecciosas

Enfermedades Infecciosas

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Campo J, Cano J, del Romero J, Hernando V, del Amo J, Moreno S.

    Role of the dental surgeon in the early detection of adults with underlying HIV infection/AIDS

    MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL . 17(3): 401-408. Nº de citas: 3

    [doi:10.4317/medoral.17527]

  • Navarro M, Navaza B, Guionnet A, López-Vélez R.

    A multidisciplinary approach to engage VFR migrants in Madrid, Spain

    TRAVEL MEDICINE AND INFECTIOUS DISEASE . 10(3): 152-156. Nº de citas: 9

    [doi:10.1016/j.tmaid.2012.03.001]

  • Pérez-Molina JA, Mora Rillo M, Suárez-Lozano I, Casado-Osorio JL, Teira Cobo R, Rivas González P, Pedrol Clotet E, Hernando-Jerez A, Domingo P, Barquilla Díaz E, Esteban H, González-García J.

    Response to Combined Antiretroviral Therapy According to Gender and Origin in a Cohort of Naive HIV-Infected Patients: GESIDA-5808 Study

    HIV CLINICAL TRIALS . 13(3): 131-141. Nº de citas: 11

    [doi:10.1310/hct1303-131]

  • Odolini S, Parola P, Gkrania-Klotsas E, Caumes E, Schlagenhauf P, López-Vélez R, Burchard GD, Santos-O'Connor F, Weld L, von Sonnenburg F, Field V, de Vries P, Jensenius M, Loutan L, Castelli F.

    Travel-related imported infections in Europe, EuroTravNet 2009

    CLINICAL MICROBIOLOGY AND INFECTION . 18(5): 468-474. Nº de citas: 49

    [doi:10.1111/j.1469-0691.2011.03596.x]

  • Moreno S.

    Earlier initiation of antiretroviral therapy after start of antituberculosis therapy reduced mortality in HIV

    ANNALS OF INTERNAL MEDICINE . 156(6): .

    [doi:10.7326/0003-4819-156-6-201203200-02002]

  • Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G, CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group.

    Differences in HIV Natural History among African and Non-African Seroconverters in Europe and Seroconverters in Sub-Saharan Africa

    Plos One . 7(3): . Nº de citas: 26

    [doi:10.1371/journal.pone.0032369]

  • Miró JM, Blanes M, Norman F, Martín-Dávila P.

    Infections in solid organ transplantation in special situations: HIV-infection and immigration.

    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA . 30 Suppl 2: 76-85.

    [doi:10.1016/S0213-005X(12)70086-1]

  • Macías J, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, de Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Pineda JA.

    Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients

    HIV CLINICAL TRIALS . 13(2): 61-69. Nº de citas: 16

    [doi:10.1310/hct1302-61]

  • Fortún J, Ruiz I, Martín-Dávila P, Cuenca-Estrella M.

    Fungal infection in solid organ recipients.

    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA . 30 Suppl 2: 49-56.

    [doi:10.1016/S0213-005X(12)70082-4]

  • Pérez-Molina JA, Díaz-Menéndez M, Plana MN, Zamora J, López-Vélez R, Moreno S.

    Very late initiation of HAART impairs treatment response at 48 and 96 weeks: results from a meta-analysis of randomized clinical trials

    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY . 67(2): 312-321. Nº de citas: 15

    [doi:10.1093/jac/dkr478]

  • Pineda JA, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, de Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Macías J.

    Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis

    JOURNAL OF INFECTION . 64(2): 204-211. Nº de citas: 7

    [doi:10.1016/j.jinf.2011.10.016]

  • Fernàndez-Sabé N, Cervera C, Fariñas MC, Bodro M, Muñoz P, Gurguí M, Torre-Cisneros J, Martín-Dávila P, Noblejas A, Len O, García-Reyne A, Del Pozo JL, Carratalà J.

    Risk Factors, Clinical Features, and Outcomes of Toxoplasmosis in Solid-Organ Transplant Recipients: A Matched Case-Control Study

    CLINICAL INFECTIOUS DISEASES . 54(3): 355-361. Nº de citas: 80

    [doi:10.1093/cid/cir806]

  • Yebra G, de Mulder M, Martín L, Rodríguez C, Labarga P, Viciana I, Berenguer J, Alemán MR, Pineda JA, García F, Holguín A.

    Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses.

    JOURNAL OF CLINICAL MICROBIOLOGY . 50(2): 407-413. Nº de citas: 34

    [doi:10.1128/JCM.05798-11]

  • Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O, EuroSIDA study group.

    Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy

    AIDS . 26(3): 315-323. Nº de citas: 26

    [doi:10.1097/QAD.0b013e32834e8805]

  • Tejada Evans AD, Ortega-Sánchez G, Moreno Guillén S.

    Síndrome de coloración púrpura de la orina.

    REVISTA CLINICA ESPANOLA . 212(1): .

    [doi:10.1016/j.rce.2011.11.002]

  • Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD.

    The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression

    ANTIVIRAL THERAPY . 17(7): 1291-1300. Nº de citas: 6

    [doi:10.3851/IMP2407]

  • Jarrin I, Pantazis N, Gill MJ, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, de Olalla PG, Porter K, del Amo J.

    Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia

    CLINICAL INFECTIOUS DISEASES . 54(1): 111-118. Nº de citas: 15

    [doi:10.1093/cid/cir814]

  • Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL, Study 145 Team.

    Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

    LANCET INFECTIOUS DISEASES . 12(1): 27-35. Nº de citas: 138

    [doi:10.1016/S1473-3099(11)70249-3]